Another MEK inhibitor, selumetinib (AZD6244, AstraZeneca), showed no superior effect in pancreatic cancer patients when compared with conventional cytotoxic chemotherapy [10]. The gene discussed is MAP2K7; the disease is familial pancreatic carcinoma.